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Abstract
Background As treatment for chronic hepatitis C (HCV)
virus has evolved to all-oral, interferon-free directly acting
antiviral (DAA) therapy, the impact of these improvements
on patient adherence has not been described.
Methods Medication adherence was measured in 60
HCV, genotype-1, treatment-naı¨ve participants enrolled in
a phase 2a clinical trial at the National Institutes of Health
and community clinics. Participants received either
ledipasvir/sofosbuvir (LDV/SOF) (90 mg/400 mg) (one
pill) daily for 12 weeks, LDV/SOF ? GS-9451
(80 mg/day) (two pills) daily for 6 weeks, or LDV/
SOF ? GS-9669 (500 mg twice daily; three pills, two in
the morning, one in the evening) for 6 weeks. Adherence
was measured using medication event monitoring system
(MEMS) caps, pill counts and patient report.
Results Overall adherence to DAAs was high. Adherence
declined over the course of the 12-week treatment
(p = 0.04). While controlled psychiatric disease or symp-
toms of depression did not influence adherence, recent drug
use was a risk factor for non-adherence to 12-week
(p = 0.01), but not 6-week regimens. Adherence as mea-
sured by MEMS was lower than by patient report.
Conclusions Adherence to short courses of DAA therapy
with 1–3 pills a day was excellent in an urban population
with multiple risk factors for non-adherence.
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Introduction
Chronic hepatitis C virus (HCV) affects over 180 million
people worldwide and results in approximately 300,000
deaths annually due to cirrhosis and 200,000 deaths due to
hepatocellular cancer [1]. Treatment for HCV has rapidly
evolved—from complex regimens associated with multiple
toxicities that require weekly injections of pegylated-in-
terferon (IFN) in combination with eight pills a day for
12–48 weeks—to new regimens of all-oral directly acting
antiviral (DAA) agents only characterized by low pill
burdens, short therapeutic courses, few side effects, and
high ([90 %) rates of sustained virologic response (SVR)
[2–9]. Most recently, the DAA-only regimen consisting of
a fixed-dose combination of ledipasvir and sofosbuvir
(LDV/SOF) was approved by the Food and Drug Admin-
istration (FDA) for the treatment of chronic HCV genotype
1 (GT-1) infection [9].
Evaluating adherence to DAA-only regimens is vital to
translating the high efficacy of these regimens observed in
phase III clinical trials to the community. In particular,
adherence is important to attaining the maximal rate of
SVR from a treatment regimen, avoiding treatment failure
and/or the development of DAA resistance [7, 8]. Addi-
tionally, the cost of medication non-adherence across all
diseases has been estimated to exceed $100 billion in
additional healthcare expenditures [6]. Given the high cost
of HCV DAA medications, which has driven some insurers
to implement rules authorizing only one course of DAA
therapy in a patient’s lifetime, maximizing SVR rates is
especially important [10, 11].
While low adherence (\80 %) to IFN-containing regi-
mens without DAAs has been shown to result in decreased
rates of SVR, the impact of patient adherence on outcomes
in DAA-only therapy has not been established [12]. As
RNA virus, HCV rapidly replicates and is highly error
prone, suggesting that it could develop high-level resis-
tance to DAAs [7, 13]. The subsequent risk of emerging
class-specific viral mutants at treatment failure may restrict
future treatment options [14]. Therefore, understanding the
impact of duration, pill burden, and patient psychosocial
factors on adherence to DAA-only regimens is critical to
developing simple, efficacious treatments vital to achieving
global eradication of HCV.
To evaluate the potential impact of patient adherence to
HCV treatment on outcomes, the adherence of patients
enrolled in three arms of the NIH SYNERGY trial was
measured.
Patients and methods
Study design and patients
The SYNERGY study was designed to investigate whether
the addition of a third potent DAA to LDV/SOF enables
treatment duration to be shortened from 12 to 6 weeks,
while maintaining high efficacy. Sixty HCV mono-in-
fected, treatment-naı¨ve, GT-1 patients were enrolled into
one of three arms in this phase 2a clinical trial and
received: LDV/SOF (90 mg/400 mg) one pill once
daily for 12 weeks (n = 20), LDV/SOF ? GS-9451
(80 mg/day) two pills once daily for 6 weeks (n = 20), or
LDV/SOF ? GS-9669 (500 mg/day) three pills (two of
LDV/SOF and GS-9669 in the morning and one of GS-
9669 in the evening) for 6 weeks (n = 20) (Fig. 1). Full
inclusion and exclusion criteria have been previously
published [15]. Written or oral informed consent approved
by the National Institute of Allergy and Infectious Diseases
(NIAID) Institutional Review Board (IRB) was obtained
from all participants.
Community model: DC partnership for AIDS/HIV
progress
The DC Partnership For AIDS Progress (DC-PFAP) is a
collaborative initiative funded by the Office of AIDS
Research to improve the care of HIV-infected subjects in
the District of Columbia in collaboration with the DC
Department of Health and the National Institutes of Health
(NIH). As part of this program, a hepatitis subspecialty
team treats HCV at multiple clinics established within
community health centers in Washington, DC. All
screening and day 0 (study medication initiation) visits
took place at the NIH Clinical Center. Subsequent study
visits were performed at the community subspecialty
clinics or at the NIH based on subject preference. Patients
referred through DC-PFAP belonged to an inner-city
population reflective of the US HCV epidemic.
Main outcome measures
Primary outcome in this substudy was adherence as mea-
sured by three tools: medication event monitoring system
(MEMS) caps, pill counts, and patient reports. We aimed to
describe adherence to novel DAA-only treatment regimens
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and to investigate the risk factors associated with non-ad-
herence to these regimens.
Adherence measures
Adherence visits occurred at day 0 (start of study drug) and
end of treatment for all patients. Patients treated with the
12-week regimen had additional adherence visits at weeks
1, 4, and 8 (Fig. 1). During day 0 adherence visits, patients
were provided seven standardized points describing the
adherence tools (Supplemental Table 1) and were assured
that non-adherence would not affect study participation. In
order to maintain optimal levels of study medications in
their blood, patients were counseled to take the study
medications at approximately the same time every day. A
dose taken correctly was measured within a time frame of
24 ± 2 h from the previous dose, except in the case of GS-
9669, which was to be taken 12 h ± 2 h from the previous
dose. Patients were instructed to bring their medication
bottles to each study visit so that the study team could
perform a pill count and collect MEMS data. Results of
adherence tools were collected by clinical trial staff and
entered into an electronic database. Results were reviewed
weekly by the principal investigator, but, with one excep-
tion, were not discussed with patients.
Medication event-monitoring systems (MEMS)
Electronic MEMSCaps (MWV Switzerland Ltd., Sion,
Switzerland) were placed on study medication bottles at day
0. Patients treated with LDV/SOF for 12 weeks had medi-
cation refills at weeks 4 and 8, and MEMSCaps were
transferred to the new pill bottles by study team members at
these time points. Patients treated on the 6-week regimens
of LDV/SOF and GS-9451 or GS-9669 received all 6 weeks
of medication at day 0. For patients taking multiple pills,
color-coded MEMSCaps were placed on color-coded bot-
tles to help patients more easily match the correct cap to its
bottle. Dosing history (including date and time of dose and
missed doses) was blindly extracted from MEMSCaps
[Advanced Analytical Research on Drug Exposure Group
(AARDEX), Sion, Switzerland] at each adherence visit.
Pill count
The number of pills remaining in each patient’s bottles as
well as the number of pills dispensed were recorded at each
adherence visit and were used to calculate the total number
of missed doses between adherence visits.
Patient report
The study team adapted questionnaires previously devel-
oped and validated by the AIDS Clinical Trials Group
(ACTG), which were widely used for measuring adherence
and risk factors for non-adherence to HIV antiviral drugs
[16]. Questionnaires assessed three main areas: (1) adher-
ence self-efficacy and beliefs about medication effective-
ness, (2) psychological distress and social support
including questions from the Center for Epidemiological
Studies Depression (CES-D) scale (total of seven four-
point items) and the Perceived Stress Scale (total of four
five-point items), and (3) alcohol and drug use [16].
Baseline and follow-up ACTG questionnaires were modi-
fied for this study to be applicable for patients infected with
HCV alone (Supplemental Text 1–4). Baseline question-
naires were administered at day 0 and follow-up ques-
tionnaires at subsequent adherence visits. Clinical trial staff
was available to read questionnaires to patients with low
literacy and were available to patients with questions.
Fig. 1 Study design and
adherence visits
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Statistical analysis
Adherence across and within treatment arms was compared
using ANOVA and t tests. Means and standard errors are
reported. Risk factors for non-adherence were assessed
using chi-squared tests, t tests, or Pearson’s correlations as
appropriate. Multivariate analyses were not performed,
given the small sample size.
Results
Demographics and patient characteristics are shown in
Table 1. Eighty-seven percent of study participants were
recruited from HCV clinics associated with the DC-PFAP
program. While some patients chose to remain at the
NIH Clinical Center, the majority of patients (57 %)
transitioned back to their community clinics at or after
week 4.
Most patients were male (72 %), African American
(88 %), had a high-school degree or less (63 %), and had a
diagnosed psychiatric disease (57 %). Ten percent, 17, 8,
and 5 % of patients had abused alcohol, marijuana,
cocaine, and/or heroin, respectively, in the 6 months prior
to starting the study medications. Twenty-seven percent of
patients were employed outside of their home. Intravenous
drug use (IVDU) was the most common self-reported risk
factor for HCV (52 %), followed by IVDU along with
blood transfusions (15 %) and blood transfusions alone
(7 %). Twenty-eight percent of patients did not answer or
did not know their risk factors for HCV infection.
High adherence to medications by MEMS, pill
counts, and patient report
Adherence to DAAs was high as measured by MEMS, pill
count, and patient report. In patients treated with 12 weeks
of LDV/SOF in a once daily combination tablet, the overall
adherence was 97.6, 98.2, and 99.3 % by MEMS, pill
count, and patient report, respectively. In patients treated
with LDV/SOF and GS-9451 for 6 weeks with two pills
once daily, overall adherence was 97.3, 98.2, and 99.3 %
by MEMS, pill count, and patient report, respectively. In
the regimen using LDV/SOF and GS-9669 with three pills
(two in the morning, one in the evening) daily, overall
adherence was 95.0, 98.9, and 99.5 % by MEMS, pill
count, and patient report, respectively (Fig. 2). There was
no difference in overall adherence among the three regi-
mens by MEMS (p = 0.36), pill count (p = 0.60), or
patient report (p = 0.84).
Table 1 Demographics and baseline characteristics
Ledipasvir/sofosbuvir (n = 20) Ledipasvir/sofosbuvir
? GS-9451 (n = 20)
Ledipasvir/sofosbuvir
? GS-9669 (n = 20)
p value
Age (years) 57 ± 8 54 ± 9 54 ± 7 0.28
Male 14 (70) 16 (80) 13 (65) 0.56
Black race* 16 (80) 18 (90) 19 (95) 0.32
History of psychiatric diagnosis n = 11 n = 10 n = 13
Bipolar D/o 3 (27) 1 (10) 2 (15) 0.62
Depression 4 (37) 6 (60) 6 (46)
Schizophrenia 1 (9) 1 (10) 0 (0)
Other 3 (27) 2 (20) 5 (39)
Alcohol consumption last 30 days (Y) 1 (5) 2 (10) 3 (15) 0.37
Marijuana last 6 months (Y) 6 (30) 2 (10) 6 (30) 0.48
Cocaine last 6 months (Y) 2 (10) 1 (5) 2 (10) 0.96
Heroin last 6 months (Y) 0 (0) 1 (5) 2 (10) 0.40
Highest education[ 12th grade 9 (45) 6 (30) 7 (35) 0.17
Work for pay outside the home (Y) 9 (45) 3 (18) 4 (22) 0.14
Self-reported risk for HCV
Shared drug paraphernalia 9 (45) 10 (50) 11 (55) 0.99
Blood transfusion 3 (15) 1 (5) 0 (0)
Shared drug paraphernalia ? blood transfusion 2 (10) 3 (15) 4 (20)
Don’t know/not reported 14 (70) 16 (80) 14 (70)
Data are mean (SD) or n (%)
HCV hepatitis C virus
* Race was self-reported
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Within each regimen, adherence as measured by MEMS
was consistently lower than that measured by patient self-
report (LDV/SOF, p = 0.002; LDV/SOF ? GS-9451,
p = 0.01; LDV/SOF ? GS-9669, p = 0.01). Conversely,
adherence as measured by MEMS was similar to that
reported by pill count for the one-pill and two-pill per day
treatment arms (LDV/SOF, p = 0.13; LDV/SOF ? GS-
9451, p = 0.28), but was significantly lower than that by
pill count for patients receiving the three pill per day
regimen of LDV/SOF and GS-9669 (p = 0.04). There was
no significant difference in adherence as measured by
pill count and patient report (LDV/SOF, p = 0.15;
LDV/SOF ? GS-9451, p = 0.15; LDV/SOF ? GS-9669,
p = 0.26) (Fig. 2).
Self-reported reasons for missed doses by MEMS or pill
count are summarized in Table 2. The most common rea-
sons included, ‘‘feeling as if the treatment was working’’
(38 %), ‘‘forgetting’’ (35 %), and ‘‘being away from
home’’ (32 %).
Adherence results were not discussed with patients in
order to mimic a ‘‘real-world’’ clinic experience where
MEMS data would not be routinely available. One
exception was a single patient who by MEMS was found to
have missed five doses by the week 4 visit. Given that the
patient had advanced liver disease with cirrhosis, the
principal investigator decided that the risk of not counsel-
ing the patient outweighed any benefit to the adherence
study. The patient was counseled by a study physician to
improve adherence but subsequently missed six additional
doses over the next 8 weeks.
Pill burden and adherence to DAAs
In order to assess the impact of pill burden on adherence,
adherence during the initial 6 weeks of therapy was
compared across treatment arms. A trend toward lower
adherence was observed in the LDV/SOF ? GS-9669
three pill per day regimen (two in the morning, one
at night) as compared to the LDV/SOF one pill per day
regimen (1 pill/day: 98.2 ± 0.02 % vs. 3 pills/day:
95.0 ± 1.75 %; p = 0.07) (Fig. 3).
Adherence to DAAs declines with increasing
treatment duration
To control for the influence of pill burden while deter-
mining the impact of treatment duration on adherence,
adherence of participants over the course of the 12-week
regimen of LDV/SOF was compared. Adherence to this
regimen as measured by MEMS declined over the course
of therapy (week 0–4: 98.1 ± 0.9 % vs. week 8–12:
95.0 ± 1.2 %; p = 0.04) (Fig. 4).
Demographic risk factors for non-adherence
to directly acting antiviral therapy
In a univariate analysis of demographic and baseline
characteristics, mean adherence did not differ based on
psychiatric disease, symptoms of depression (i.e., CES-D
score C 8), perceived stress level (PSS), gender, education,
work status, children, or patient perceived self-efficacy
(Table 3) [17, 18].
In the 12-week treatment arm, adherence to LDV/SOF
was significantly lower among participants who used
drugs (including marijuana, cocaine, or heroin) in the
6 months prior to starting DAA therapy or abused alcohol
([3 drinks per day or[5 drinks in a 2–4-h period at any
time during the 30 days) (p = 0.01) (Table 3, defined as
‘‘Recent substance abuse’’). However, in the 6-week
treatment arms, patients with a recent history of alcohol
abuse and/or drug use had similar adherence to the
DAA regimen as patients without this history (LDV/
SOF ? GS-9451, p = 0.19; LDV/SOF ? GS-9669,
p = 0.28).
Timing of DAA administration and consecutive
missed doses
In the LDV/SOF treatment arm, patients took 72 ± 18 %
of doses at the correct time. In the LDV/SOF and GS-9451
or GS-9669 arms, patients took 64 ± 18 and 61 ± 18 % of
doses at the correct time, respectively. There was no dif-
ference in the mean number of doses taken at the correct
time among the three regimens (LDV/SOF vs. LDV/
SOF ? GS-9451, p = 0.16; LDV/SOF vs. LDV/SOF ?
GS-9669, p = 0.08; LDV/SOF ? GS-9451 vs. LDV/
SOF ? GS-9669, p = 0.70).
Fig. 2 Adherence to DAA regimens measured by MEMS, pill count,
and patient report. *p\ 0.05 versus MEMS
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Given that missing doses of DAA therapy may increase
the risk of developing HCV resistance-associated variants
(RAV) or enrich populations of existing RAVs, we
examined the relationship between the number of consec-
utive missed doses by MEMS and enrichment of baseline
mutations [14]. Only 4 out of 60 patients missed two or
more consecutive doses of study medications by MEMS.
One patient treated with LDV/SOF for 12 weeks and one
patient treated with LDV/SOF ? GS-9669 missed two
consecutive doses. There were two additional patients on
the three-pill regimen that missed consecutive doses: one
missed three, four, and four consecutive doses, and one
missed five consecutive doses. All of these patients
achieved SVR.
Correlation of missed doses with SVR
Fifty-eight (96.6 %) of 60 patients in the study achieved
SVR. One patient relapsed 2 weeks after completion of
therapy. This patient missed one dose by both MEMS and
pill count and zero doses by patient report. The other
patient was incarcerated after achieving SVR4, and no
further data are available.
Discussion
In this phase 2a study, adherence to all-oral DAAs for HCV
treatment was high among a largely inner-city patient
population with multiple risk factors for treatment
Table 2 Self reported reasons for non-adherence among non-adherent patients by MEMS or pill count







n = 14 n = 9 n = 14 n = 37
Felt like treatment was working 8 (57) 2 (22) 4 (28) 14 (38)
Simply forgot 7 (50) 4 (44) 2 (14) 13 (35)
Away from home 6 (42) 5 (56) 1 (7) 12 (32)
Had a change in daily routine 4 (28) 2 (22) 2 (14) 8 (22)
Felt depressed/overwhelmed 6 (43) 1 (11) 0 (0) 7 (19)
Felt worse when took medication 5 (35) 0 (0) 2 (14) 7 (19)
Felt sick/ill 3 (21) 3 (33) 1 (7) 7 (19)
Fell asleep/slept through dose time 4 (28) 1 (11) 1 (7) 6 (16)
Felt like drug was harmful or toxic 3 (21) 1 (11) 0 (0) 4 (11)
Had problems taking at specified times 3 (21) 0 (0) 1 (7) 4 (11)
Felt hassled or inconvenienced by medicine 2 (14) 1 (11) 0 (0) 3 (8)
Too many pills to take 2 (14) 1 (11) 0 (0) 3 (8)
Did not want others to notice 2 (14) 1 (11) 0 (0) 3 (8)
Ran out of pills 1 (7) 0 (0) 1 (7) 2 (5)
Fig. 3 Adherence to DAAs decreases with increasing pill burden.
Adherence to DAA regimens declined with increasing pill burden
(*first 6 weeks compared between arms)
Fig. 4 Adherence to DAAs declines over 12-week treatment course.
Adherence between weeks 0–4, 98.1 ± 0.9 %, was significantly
higher than adherence between weeks 8–12, 95.0 ± 1.2 %. for
patients treated with 12 weeks of LDV/SOF
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Table 3 Risk factors for patient non-adherence to directly acting antivirals for treatment of hepatitis C





Sex: mean adherence ± SD (n)
Male 96.7 ± 0.9 (14) 0.93 96.8 ± 1.1 (14) 0.73 95.2 ± 2.6 (10) 0.87
Female 96.8 ± 1.1 (6) 97.6 ± 0.0 (3) 94.6 ± 2.5 (8)
Age* R2 = 0.02 0.59 R2 = 0.025 0.54 R2 = 0.019 0.59
Race
White 99.1 ± 0.9 (4) 0.09 96.4 ± 3.6 (2) 0.85 97.6 (1) N/A**
Black 96.1 ± 0.8 (16) 97.0 ± 0.9 (15) 94.8 ± 1.9 (17)
Highest education: mean adherence ± SD (n)
Masters 100.0 (1) 0.34*** None 0.36 None 0.88
College graduate (4 year) 100.0 (2) 95.2 ± 0.0 (1) 92.9 ± 4.8 (3)
College graduate (2 year) 95.2 ± 1.5 (6) 99.4 ± 1.2 (4) 98.8 ? 1.2 (2)
High school graduate 96.6 ± 0.9 (9) 96.6 ± 1.6 (7) 94.4 ± 3.6 (8)
11th grade or less 97.02 ± 3.0 (2) 95.7 ± 1.9 (5) 95.2 ± 1.7 (4)
Currently employed
Yes 97.8 ± 0.8 (9) 0.19 98.4 ± 1.6 (3) 0.73 98.2 ± 1.1 (4) 0.28
No 95.9 ± 1.1 (11) 97.6 ± 1.1 (11) 93.3 ± 2.5 (12)
Recent substance abuse
Yes 96.4 ± 1.4 (8) 0.01 98.4 ± 0.8 0.19 92.5 ± 3.8 (7) 0.28
No 99.4 ± 0.3 (12) 95.6 ± 1.8 (6) 96.5 ± 1.5 (11)
Diagnosed psychiatric disease
Yes 95.8 ± 1.5 (7) 0.32 97.3 ± 1.3 (7) 0.75 92.6 ± 3.4 (8) 0.23
No 97.3 ± 0.7 (13) 96.7 ± 1.3 (10) 96.9 ± 1.6 (10)
Center for Epidemiological Studies depression (CES-D) score#
CES-D C8 97.8 ± 0.6 (9) 0.40
CES-D\8 96.2 ± 0.85 (43)
Self-reported self-efficacy
You will be able to take all or most of the study medication as directed?
Not at all/somewhat/very sure 96.0 ± 1.9 (6) 0.53 95.7 ± 1.9 (5) 0.41 89.3 ± 6.5 (4) 0.08
Extremely sure 97.0 ± 0.6 (14) 97.4 ± 1.0 (12) 96.6 ± 1.2 (14)
The medication will have a positive impact on your health?
Not at all/somewhat/very sure 96.7 ± 1.1 (11) 0.73 96.6 ± 1.3 (9) 0.47 94.8 ± 2.5 (11) 0.91
Extremely sure 97.2 ± 0.9 (8) 98.0 ± 1.3 (7) 95.2 ± 2.3 (7)
In general, how satisfied are you with the overall support you get from your friends and family members?
Very or somewhat
dissatisfied/somewhat satisfied
96.8 ± 1.7 (3) 0.95 97.2 ± 1.6 (6) 0.81 89.3 ± 6.5 (4) 0.08
Very satisfied 96.7 ± 0.79 (17) 96.8 ± 1.2 (11) 96.6 ± 1.2 (14)
To what extent do your friends or family members help you remember to take your medication?
Not at all/A little/somewhat 96.6 ± 0.8 (8) 0.47 98.6 ± 1.0 (5) 0.53 95.2 ± 2.3 (7) 0.82
A lot 96.2 ± 1.3 (9) 96.3 ± 1.5 (9) 95.9 ± 2.2 (7)
Not applicable 98.8 ± 1.2 (3) 96.0 ± 2.1 (3) 92.9 ± 6.3 (4)
Do you have any children?
Yes 96.3 ± 0.8 (15) 0.27 97.4 ± 1.2 (10) 0.92 92.9 ± 1.7 (12) 0.61
No 98.1 ± 1.2 (5) 97.1 ± 1.9 (5) 91.1 ± 3.1 (4)
Do any children live with you?
Yes 97.4 ± 0.7 (15) 0.09 97.9 ± 1.1 (9) 0.90 95.9 ± 1.9 (11) 0.30
No 94.4 ± 2.3 (4) 97.6 ± 1.8 (5) 91.4 ± 4.7 (5)
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noncompliance. Although adherence declined with
increases in pill burden and treatment duration, mean
adherence as measured by MEMS did not fall below 95 %
irrespective of these factors. Recent drug use was associ-
ated with decreased treatment compliance in the 12-week
arm, but not in the 6-week arms. Additionally, neither
concomitant controlled mental illness nor symptoms of
anxiety or depression influenced adherence. Due to the
efficacy of DAA regimens and the high adherence observed
in this study, no risk factors could be associated with viral
relapse. Overall, simple, short-duration, all-oral HCV
therapy in patients with perceived risk factors for treatment
noncompliance may be as efficacious as in populations
without these risk factors.
The development of DAAs has dramatically simplified
treatment for hepatitis C by improving cure rates and
decreasing side effects [2–4, 19]. The real-world effec-
tiveness of all-oral, interferon- and ribavirin-free DAA
regimens is similar to that seen in clinical trials [20, 21].
Given that missed doses of HCV treatment may result in
the potential development of viral resistance, adherence to
these DAA medications remains an important issue as
larger numbers of HCV-infected patients are treated [7, 14,
22].
Participants in this study were generally representative
of the patient population infected with HCV in the USA
and demonstrated sociodemographic characteristics asso-
ciated with medication non-adherence [23–25]. Although
patients with active drug use, active alcohol abuse, or
uncontrolled psychiatric disease were excluded from the
study, diagnosed psychiatric disease was common, and
many patients reported recent drug use. Data from this
study show that medication adherence in patients with
stable psychiatric disease or symptoms of depression (as
measured by CES-D) is similar to that in patients without
psychiatric disease [26]. Recent drug use was associated
with decreased adherence in patients treated with the
longer 12-week treatment duration, suggesting that shorter,
simple regimens may be better for this patient population.
These regimens may be administered in the setting of drug
rehabilitation for patients not at high risk of HCV
reinfection, where additional monitoring and adherence
support is available.
Adherence as measured by the MEMS and pill count
was similar between the one-pill (LDV/SOF) and two-pill
(LDV/SOF ? GS-9451) per day regimes, but a trend
toward lower adherence was observed in the three-pill
(LDV/SOF ? GS-9669) per day (two pills in the morning,
one pill at night) regimen. It is unknown whether the
additional pill burden or the additional time of pill
administration had a greater bearing on this decreased
adherence. It should be noted that for all three regimens,
adherence as measured by MEMS was lower than that
determined by patient report, but similar to that by pill
count. This supports the finding that when prompted to
report adherence rates, patients tend to overestimate their
adherence and underestimate their number of missed doses
[27]. Given the similar measurements obtained by MEMS
and pill count and the high cost of MEMS caps, clinicians
can consider pill count an alternative and reliable measure
for monitoring patient adherence.
While forgetting their medications and being away from
home were among the top reasons for patients missing
HCV medications, the most common reason, as reported by
38 % of patients, was feeling as if the medications were
working. During this study, patients would meet with a
member of the study team at each visit and discuss their
progress on study. Anecdotally, many patients were inter-
ested and happy to see their rapid HCV viral load decline
upon initiation of therapy. Patients were counseled that
these results, while promising, did not indicate SVR. Given
that many patients reported their reason for non-adherence
as feeling reassured that the medications were working,
additional counseling about the meaning of HCV viral load
decline may be needed to improve adherence, particularly
in non-study settings where patient interactions with their
provider may be more limited.
Limitations of this study include the small sample size,
which restricts the ability to perform a multivariate analysis
of risk factors for non-adherence. Since drug and alcohol
abuse was self-reported by the patients, there may be an
underestimation of these characteristics among our patient
Table 3 continued





Perceived stress score* R2 = 0.0003 0.94 R2 = 0.14 0.14 R2 = 0.029 0.50
* Pearson’s correlations
** Cannot compare with one value n = 1
*** Excluding master’s degree, which only had 1 value
# CES-D Score C8 associated with depression. Unable to perform analysis for each arm given the small numbers of patients with CES-D
score C8
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population. Additionally, adherence as studied here may be
different from real-world clinical practice. Patients in this
study were enrolled on a clinical trial to test novel DAA
therapies for the treatment of HCV and thus had frequent
study visits with their healthcare provider, which may serve
to reinforce adherence to medications. However, only one
subject who missed 11 of 84 doses had an intervention to
address poor adherence. The remaining patients were
observed, which may be comparable to a clinical setting
where adherence by MEMS caps and pill counts are not
routinely performed. The results of this study warrant
future evaluations of adherence in patients undergoing
DAA therapy in real-life settings worldwide, specifically
for those DAA-based therapies that extend over 12 weeks
and include ribavirin, which is still part of the standard of
care for HCV in most parts of the world. Given the high
degree of adherence and high percentage of SVR in this
study, we were not able to demonstrate the threshold of
adherence required to achieve SVR. This is an important
clinical question that needs to be addressed in future clin-
ical trials with a large number of patients as DAA therapy
becomes more widely used globally.
Although several studies of adherence have addressed
issues related to long-term chronic illnesses, there are few
studies investigating adherence to shorter medical regi-
mens of 12–24 weeks or less of therapy [28, 29]. In this
study, we found that during a one-pill once-daily 12-week
regimen, adherence to medication dropped off after
4 weeks, and significantly after 8 weeks. Therefore, efforts
to devise DAA regimens for HCV treatment of no longer
than 8 weeks should be encouraged.
In conclusion, adherence to DAAs was high in this
urban population of patients who are representative of the
HCV epidemic in the US [23]. Numerous potent regimens
are in development for the treatment of HCV, thereby
providing clinicians with multiple options for their patients
[3, 4, 15, 19, 30]. When selecting the optimal treatment,
clinicians should consider pill burden and treatment dura-
tion in addition to cost, adverse events, efficacy, and drug-
drug interactions. Additionally, clinicians should be aware
that HCV treatment of patients with controlled psychiatric
disease or symptoms of depression may be equally suc-
cessful as that in patients without psychiatric disease.
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